UNRESECTABLE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Clinical trials for UNRESECTABLE UNDIFFERENTIATED PLEOMORPHIC SARCOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE UNDIFFERENTIATED PLEOMORPHIC SARCOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE UNDIFFERENTIATED PLEOMORPHIC SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major cancer trial aims to boost survival for Tough-to-Treat tumors
Disease control Recruiting nowThis large, late-stage trial is testing whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (doxorubicin) works better than chemotherapy alone for people with advanced or inoperable sarcomas. The goal is to see if the combination helps patients live long…
Matched conditions: UNRESECTABLE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Scientists test Two-Pronged attack on Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new combination of two drugs, peposertib and liposomal doxorubicin, for people with advanced soft tissue sarcomas that have spread or cannot be removed by surgery. The main goal is to find the safest and most effective dose of this drug pair. R…
Matched conditions: UNRESECTABLE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC